Samer A. Srour, MB, ChB, MS, assistant professor in the Department of Stem Cell Transplantation and Division of Cancer Medicine at the University of Texas MD Anderson Cancer Center, spoke with CancerNetwork at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting about results observed in a phase 2 (NCT01729091) which assessed the use of umbilical cord bloodderived natural killer cells with elotuzumab (Empliciti), lenalidomide (Revlimid), and high-dose melphalan (Evomela) followed by autologous stem cell transplantation for patients with high-risk multiple myeloma.
Srour noted a progression-free survival (PFS) rate of 83% and an overall survival (OS) rate of 97% among patients who were treated with the regimen.
This expansion phase 2 cohort was included in the final platform of elotuzumab, lenalidomide, and the cord bloodderived expanded [natural killer] cells. We started this in early 2018, and we accrued the last patient in early 2021, so over 2 years. Despite COVID, we were able to accrue very well on this study. Now we have mature data after an immediate follow-up of 26 months for these 30 patients who all have high-risk multiple myeloma. Historically, we know the median survival is short, [about] less than 3 to 5 years, and with all the new treatments in myeloma, we were not able to overcome much of the resistance in [many] of the high-risk patients.
Thirty patients were included in this study over a 2 plus year period. The primary end point was best response rate on day 100 after transplant, [including] VGPR, very good partial response or better, and MRD [minimal residual disease] negativity at day 100 after transplant. We gave this regimen in the context of the transplant. Patients took elotuzumab, lenalidomide, and high-dose melphalan [followed by] the [natural killer] cells. After that, we gave them back their autologous stem cells, and then they were engrafted as with any other [patients with] myeloma. They engrafted on time within 10 to 11 days from the transplant. We looked at the best response at 3 months after transplant before getting any other treatments. We found out that the VGPR or better was 97%. We dont see that in the high-risk [patients with] myeloma. The MRD negativity rate was 75%. [This is also rarely] seen in high-risk [patients with] myeloma even after transplant.
The primary endpoint was very impressive for us. We waited over 2 years to show [whether] this MRD-negativity rate and the VGPR translate to better progression-free survival [PFS] and overall survival [OS]. We found out that the 2-year PFS was 83%which historically [has been] around 60% or lessand then the OS was 97%. Only 1 patient died from COVID-19 infection.
This is a new regimen, and its being used in a new era where theres many other treatments; maybe the outcomes are better because of other confounders. We looked around the same time period of 2018 to 2021, and we chose a control of high-risk [patients with] myeloma who were treated with us at MD Anderson. We looked at the data to compare our study patients to these control patients who were treated homogeneously in the same way, but without the [natural killer] cells without the elotuzumab without the lenalidomide. We found a statistically significant improvement in our study patients compared [with] the control. In the control arm, the 2-year, PFS was only 60%, and the 2-year OS was only 83%. Thats compared [with] 83% PFS in our study and 97%; it is statistically significant.
Srour SA, Mehta RS, Shah N, et al. Phase II study of umbilical cord bloodderived natural killer (CB-NK) cells with elotuzumab, lenalidomide, and high-dose melphalan followed by autologous stem cell transplantation (ASCT) for patients with high-risk multiple myeloma (HRMM). J Clin Oncol. 2022;40(suppl 16):8009-8009. doi:10.1200/JCO.2022.40.16_suppl.8009
See the original post here:
Samer A. Srour, MB, ChB, MS, Reviewed Findings of CB-NK Cells and Elotuzumab Regimen in High-Risk Multiple Myeloma - Cancer Network
- New Atlas of Rare Stem and Progenitor Cells Reveals New Cell Types - Inside Precision Medicine - March 28th, 2024
- Instructing iPS cell-derived mesenchymal stem cells to inhibit abnormal bone formation in FOP - Medical Xpress - March 28th, 2024
- GLP podcast: GE crops have lived up to the hype; Growing 'mini' organs from stem cells; How do we solve right-wing ... - Genetic Literacy Project - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Stem cells: past, present, and future - PMC - National Center for ... - March 19th, 2024
- Stem cells: a comprehensive review of origins and emerging clinical ... - March 19th, 2024
- Biology of stem cells: an overview - PMC - National Center for ... - March 19th, 2024
- What are Stem Cells? - Types, Applications and Sources - BYJU'S - March 19th, 2024
- Stem Cell - The Definitive Guide | Biology Dictionary - March 19th, 2024
- Colossal Creates Elephant Stem Cells for the First Time in Quest to Revive the Woolly Mammoth - Singularity Hub - March 19th, 2024
- Florida congresswoman sued the Pentagon over stem cells. One problem: her husband's stocks - Raw Story - January 23rd, 2024
- Can Stem Cells Improve Knee Pain or Are They A Waste of Money? - Bloomberg - January 23rd, 2024
- Stem cells used to successfully treat arthritis in gorilla at Budapest zoo - University of Sheffield News - January 23rd, 2024
- A computational model of stem cells' internal mechanism to recapitulate spatial patterning and maintain the self ... - Nature.com - January 23rd, 2024
- Advancing the generation of in-vivo chimeric lungs in mice using rat-derived stem cells - EurekAlert - January 6th, 2024
- 'I couldn't just give up on my dad' | Round Rock son donates stem cells to father battling leukemia - KVUE.com - January 6th, 2024
- Closing in on the ultimate quest to regenerate insulin in pancreatic stem cells - Medical Xpress - January 6th, 2024
- Ask the doctors: Research being conducted on using stem cells to treat diabetes - The Spokesman Review - January 6th, 2024
- Regenerative Medicine and COPD: Generating Functional Lungs from Pluripotent Stem Cells - Medriva - January 6th, 2024
- What is a stem cell? YourGenome - December 2nd, 2023
- Stem cell transplant - NHS - December 27th, 2022
- Stem cells: a brief history and outlook - Science in the News - December 27th, 2022
- RUDN Physician And Russian Scientists Investigate Long-term Effects Of Treating Diabetic Ulcers With Stem Cells - India Education Diary - December 27th, 2022
- Stem Cell Basics | STEM Cell Information - National Institutes of Health - December 2nd, 2022
- Neural stem cell - Wikipedia - November 24th, 2022
- Donate Stem Cells | Bone Marrow Donation - American Cancer Society - November 24th, 2022
- Stem Cells- Definition, Properties, Types, Uses, Challenges - November 6th, 2022
- Brothers from Karnataka, Prapul and Prajwal donated their stem cells, save two blood cancer patients - APN News - November 6th, 2022
- Getting These Stem Cells Treatments: Crippled Ronnie Coleman Gives a Positive Update on His Ability to Walk - EssentiallySports - October 21st, 2022
- Cornell Prof Explains Relevance of Creating Mouse Embryos from Stem Cells - Cornell University The Cornell Daily Sun - October 13th, 2022
- Human neuron clusters transplanted into rats offer new tool to study the brain : Shots - Health News - NPR - October 13th, 2022
- The neuroprotective effects of dental pulp stem cells and erythropoietin in mice hippocampus after ischemia-reperfusion - Newswise - October 13th, 2022
- A $7 million grant to grow stem cell research - Swinburne University of Technology - October 13th, 2022
- Stem Cell Manufacturing Global Market Report 2022: Widespread Product Utilization in Effective Disease Management, Personalized Medicine, and Genome... - October 13th, 2022
- Brennand named Elizabeth Mears and House Jameson Professor of Psychiatry - Yale News - October 13th, 2022
- American Academy of Stem Cell Physicians to Offer Licensed Physicians Board Examination in Regenerative Medicine - BioSpace - October 13th, 2022
- Stem Cells - alsa.org - October 4th, 2022
- Mouse embryo models built from stem cells take shape in a dish - Nature.com - October 4th, 2022
- Growth in Cell and Gene Therapy Market - Pharmaceutical Technology Magazine - October 4th, 2022
- Therapeutic Solutions International Identifies CD103 Expressing Dendritic Cells and Exosomes Thereof as Novel Mechanism for JadiCell Mesenchymal Stem... - October 4th, 2022
- Aileron Therapeutics Announces Oral Presentation of Non-Clinical Data Demonstrating ALRN-6924 Protected Human Hair Follicles and Their Stem Cells from... - October 4th, 2022
- Research Shows Promise for Directing Later Lines of Therapy for Hodgkin Lymphoma - Targeted Oncology - October 4th, 2022
- Hereditary E200K mutation within the prion protein gene alters human iPSC derived cardiomyocyte function | Scientific Reports - Nature.com - September 25th, 2022
- How To Eat Your Way to Better Health According to a Doctor - Eat This, Not That - September 25th, 2022
- Phio Pharmaceuticals Announces Preclinical Data Demonstrating PH-762 Enhances Persistence of T cells for Tumor Cell Killing as Presented by Helmholtz... - September 25th, 2022
- Types of blood cancer: Leukemia, lymphoma, and more - Medical News Today - September 25th, 2022
- September: er-blood | News and features - University of Bristol - September 25th, 2022
- Here Is Why You Heal Slower As You Age - Health Digest - September 25th, 2022
- Global Single Cell Analysis Market is Projected to Grow at a CAGR of 15.1% By 2032: Visiongain Reports Ltd - Yahoo Finance UK - September 25th, 2022
- Findings explain exceptional auditory abilities in Williams-Beuren Syndrome - EurekAlert - September 25th, 2022
- Finding the potency in planarians | Communications Biology - Nature.com - September 16th, 2022
- Life-Saving Innovations in Cancer-Fighting Stem Cell Transplants and Pioneering Research in HIV, Autism and Cerebral Palsy to be Featured at World... - September 16th, 2022
- Treating Cancer with Oncolytic Viruses - BioPharm International - September 16th, 2022
- Israel's Profuse Technology Raises $2.5M for Technology That Lowers Cost of Cultured Meat - The Spoon - September 16th, 2022
- Stem Cells Used to Grow Mouse Embryo - BioTechniques - September 8th, 2022
- Largest Gift in UCSD History to Fund Stem Cell Research on Space Station - Times of San Diego - September 8th, 2022
- Global Induced Pluripotent Stem Cells Market (2022 to 2027) - Growth, Trends, Covid-19 Impact and Forecasts - ResearchAndMarkets.com - Business Wire - September 8th, 2022
- Health on the Frontlines: The Healing Power of Stem Cells - Dans Papers - September 8th, 2022
- Top 3 grants in regenerative medicine: July 2022 - RegMedNet - September 8th, 2022
- Childhood leukemia treatment 2022: Where we are now and what it takes - EurekAlert - September 8th, 2022
- Treatment Choices for AML Were Increasingly Influenced by Immunological Responses - Physician's Weekly - September 8th, 2022
- BioRestorative Therapies to Present at the H.C. Wainwright 24th Annual Global Investment Conference on September 14 - StreetInsider.com - September 8th, 2022
- Global Recombinant Cell Culture Supplements Market Report 2022: Increasing Need for Immunotherapies and Stem Cell and Regenerative Medicines Presents... - September 8th, 2022
- CAR-T Beyond CGTs In Development In 2022 - BioProcess Online - September 8th, 2022
- ADOCIA Announces First Cell Therapy Preclinical Proof of Concept of AdoShell Islets for the Treatment of Type 1 Diabetes - Business Wire - September 8th, 2022
- Synthetic Mouse Embryo with Brain and Beating Heart Grown from Stem Cells - Genetic Engineering & Biotechnology News - August 30th, 2022
- Utilization of Modified Induced Pluripotent Stem Cells as the Advance | OPTH - Dove Medical Press - August 30th, 2022
- Rise In Number Of CROS In Various Regions Such As Europe Is Expected To Fuel The Growth Of Induced Pluripotent Stem Cell Market At An Impressive CAGR... - August 30th, 2022
- Brush Up: Hematopoietic Stem Cells and Their Role in Development and Disease Therapy - The Scientist - August 30th, 2022
- Regenerative Properties of the Newborn Heart Offers Hope for Those With Congenital Heart Disease - The Epoch Times - August 30th, 2022
- Kanpur hospital is Indias first to perform fat-derived stem cell transplant for diabetic patients - India Today - August 30th, 2022
- Scientists Just Genetically Edited a Million Years of Evolution Into Mouse DNA - ScienceAlert - August 30th, 2022
- Canadian Blood Services Stem Cells for Life - August 22nd, 2022
- Scientists say they have created 'embryos' without sperm or eggs - Medical News Today - August 22nd, 2022
- Many stem cell lines used for research and therapies carry large number of mutations, Cambridge researchers find - Cambridge Independent - August 22nd, 2022
- Scientists hope to revive extinct mammal through stem cells and gene-editing in a first - The Mirror - August 22nd, 2022
- Stem cell therapy in capsule form - Malaya - August 22nd, 2022
- Cell Culture Technician Pluripotent Stem Cell Biology and Genome Editing job with UNIVERSITY OF SOUTHAMPTON | 305107 - Times Higher Education - August 22nd, 2022
- Long COVID-19 and other chronic respiratory conditions after viral infections may stem from an overactive immune response in the lungs - The... - August 5th, 2022
- Self-organized anteroposterior regionalization of early midbrain and hindbrain using micropatterned human embryonic stem cells - Newswise - July 27th, 2022